What is Sarepta Therapeutics, Inc.'s SG&A?

Sarepta Therapeutics, Inc. (SRPT) reported SG&A of $133.63M in Q1 2025.

How has Sarepta Therapeutics, Inc.'s SG&A changed year-over-year?

Sarepta Therapeutics, Inc.'s SG&A increased by 5.2% year-over-year, from $127M to $133.63M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Sarepta Therapeutics, Inc. SRPT SG&A

Discontinued — last reported Q1 '25

SG&A at other companies

PfizerPFE

$2.96B-2.3%

Regeneron PharmaceuticalsREGN

$647.7M+2.3%

BioMarin PharmaceuticalsBMRN

$258.29M+25.3%

PTC TherapeuticsPTCT

$86.18M+6.5%

InsmedINSM

$247.26M+67.6%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

Segments

By segment

See full

All Other Segments$40.19M-21.4%

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.76B-63.1%

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s SG&A?: Sarepta Therapeutics, Inc. (SRPT) reported SG&A of $133.63M in Q1 2025.
How has Sarepta Therapeutics, Inc.'s SG&A changed year-over-year?: Sarepta Therapeutics, Inc.'s SG&A increased by 5.2% year-over-year, from $127M to $133.63M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.